Answers are grounded in this paper and cite their sources.
BRCA1 and BRCA2 are tumor suppressor genes that are inactivated during neoplastic development (1)(2). Germline mutations of the two genes are transmitted in the autosomal dominant fashion and predispose carriers to the development of ovarian and/or breast cancers (3)(4). Mutations in BRCA1 are present in approximately one-half of the early-onset breast cancer families and 80% of the early-onset breast and ovarian cancer families (5), whereas BRCA2 mutations are believed to account for a comparable percentage of inherited breast cancer cases (6). Women with germline mutations in BRCA1 have a lifetime risk of 85% and up to 50% for breast and ovarian cancers, respectively. In individuals of Ashkenazi Jewish background, mutations such as 185delAG and 5382insC in BRCA1, and 6174delT in BRCA2 are present in higher frequencies than other mutations because of founder effects (6)(7)(8). In one study, the three mutations accounted for 62% of Ashkenazi patients with ovarian and/or breast cancer (7). The high frequency of these mutations in the BRCA genes indicates their potential role in identifying individuals at risk. Many methods have been reported for the study of BRCA mutations, including allele-specific oligonucleotide hybridization (8)(9), allele-specific PCR (10), PCR-mediated site-directed mutagenesis (11)(12), heteroduplex analysis (HDA) (13)(14)(15), single-strand conformation polymorphism (14)(16), and the protein truncation test (14)(15). Methods such as HDA, single-strand conformation polymorphism, and the protein truncation test, which are suitable for screening uncharacterized mutations, are relatively more laborious, whereas allele-specific PCR, PCR-mediated site-directed mutagenesis, and allele-specific oligonucleotide hybridization are more efficient for screening of specific characterized mutations. Here we describe a simple and rapid method for the simultaneous detection of three common mutations: 185delAG and 5382insC in BRCA1, and 6174delT in BRCA2. Blood samples were obtained with written informed consent. DNA was extracted from peripheral blood cells as described previously (17), coded, and analyzed in a blind fashion. Allele-specific oligonucleotide primers were designed on the basis of published BRCA1 and BRCA2 sequences (18)(19) and checked against the NIH database (http://www.ncbi.nlm.nih.gov/Blast/) for possible false priming. For each mutation, three primers (one common, one specific for the mutant, and one specific for the wild-type allele) were used. The competing mutant and wild-type primers were designed to differ by ∼20 bp in size, allowing easy detection of the PCR products by routine electrophoresis and ultraviolet illumination after ethidium bromide staining. The mutant (long) and wild-type (short) primers both contain a mismatched base sequence near the 3′ end. In the early cycles of amplification, the mismatched sequences generate mutagenized PCR products that are refractory to cross-amplification by the competing primer, thereby ensuring specificity of the reaction (20). The long (mutant) primer also incorporates two additional mismatched bases at two contiguous positions corresponding to the 5′ end of the short (wild-type) primer. During the final cycles of the PCR reaction, heteroduplexes may be formed from the short and long products, but the contiguous mutagenized sequences in the long product prevent filling up of the short product by using the long strand as template. As a result, the mutant and wild-type products are separated mutagenically. The primer sequences and sizes of corresponding amplicons are shown in Table 1. Nucleotide sequences of the primer sets. Mismatched bases are underlined. Nucleotide sequences of the primer sets. Mismatched bases are underlined. PCR amplification was carried out using the GeneAmp® PCR 2400 system from Perkin-Elmer. In each PCR reaction, 25 ng of genomic DNA was added to 10 μL of reaction mixture consisting of 1× PCR reaction buffer (10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 0.01 g/L gelatin), 3.25 mmol/L MgCl2, 0.2 mmol/L dNTPs, and 50 kU/L AmpliTaq GoldTM (all from Perkin-Elmer). Allele-specific primers were added at 2.0 μmol/L for P1 and P3; 0.4 μmol/L for P2; 0.12 μmol/L for P4, P5, and P6; 0.31 μmol/L for P7 and P9; and 0.24 μmol/L for P8. Each PCR reaction consisted of an initial 12 min of AmpliTaq Gold activation at 95 °C, followed by 35 cycles of 15 s of denaturation at 94 °C, 15 s of annealing at 57 °C, and 30 s of extension (with an increment of 1 s for each subsequent cycle) at 72 °C, and a final extension step of 5 min at 72 °C. At the conclusion of the reaction, the PCR product was mixed with 2 μL of loading dye (200 g/L sucrose, 0.05 g/L bromphenol blue) and then separated on precast Clearose BG Mini (9 × 12 cm) Gels (Elchrom Scientific) by routine submerged electrophoresis (120 V, 80 min). The resolved amplicons were then stained with 0.5 mg/L ethidium bromide and viewed under ultraviolet illumination. Like other PCR techniques, mutagenically separated PCR (MS-PCR) requires careful optimization of each reaction condition, including magnesium concentration, cosolvents (dimethyl sulfoxide or glycerol), and length and temperature of cycling stages. More importantly, the concentrations (relative and absolute) of individual primers must be determined empirically to give relatively equal amplification of the wild-type and mutant alleles. If a mutation is present in one of the alleles, two bands will be present. For the 185delAG mutation, the mutant and wild-type amplicons are 354 and 335 bp, whereas those of 5382insC are 295 and 271 bp, and those of 6174delT are 171 and 151 bp. Therefore, a minimum of three bands (absence of any mutant allele) and a maximum of six bands (all three mutations) can be detected. Fig. 1 shows the electrophoretogram with patterns for zero to three mutations present in a single sample. Because at least one of the two allelic PCR products is present, MS-PCR provides an intrinsic quality control against false negatives or PCR refractory conditions. The presence of wild-type and mutant allelic products also allows easy and objective interpretation of test results. Electrophoretogram of MS-PCR products. Lane 1, 100-bp ladder; lanes 2 and 3, wild-type samples; lanes 4–6, patient samples with the 185delAG, 5382insC, and 6174delT mutations, respectively; lanes 7–9, equal volumes of 185delAG + 5382insC, 185delAG + 6174delT, and 5382insC + 6174delT, respectively; lane 10, equal volumes of each of the three mutations. M, mutant product; W, wild-type product. We evaluated this assay using a cohort of 66 Ashkenazi Jewish women at an increased risk for breast/ovarian cancer (all have a blood relative diagnosed with epithelial ovarian cancer). The genetic status of this cohort of patients had previously been ascertained by HDA (15) and DNA sequencing. Using the optimized procedure, we identified 7 individuals with the 185delAG mutation, 4 with the 5382insC mutation, 3 with the 6174delT mutation, and 52 without any of the three mutations. The results were identical to HDA and DNA sequencing, indicating the reliability of MS-PCR technique. Overall, the multiplex approach allows easy and simultaneous detection of the three mutations. This assay eliminates the need for radioisotopes, endonuclease digestion, and high-resolution electrophoresis. We conclude that this method is simple, reliable, and can be considered for routine use. Pak Cheung Chan is a recipient of a postdoctoral fellowship in Clinical Chemistry and Laboratory Medicine from the Ontario Ministry of Health, Canada We thank the Ontario Cancer Genetics Network and those who participated in the study.
No takes yet. Share an insight, caveat, or question.
Chan et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: